Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
ViiV announced, the EC has granted marketing authorisation for Triumeq® for the treatment of HIV in those aged 12+ and weighing 40kg+.
-
Ebola vaccine trials fast-tracked by international consortium
Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine
-
GSK's Promacta® (eltrombopag) receives FDA approval of an additional indication
New first-in-class treatment option for this previously treated SAA patient population
-
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
ViiV announced that the FDA has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg), treatment of HIV-1 infection.
-
GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the USA for the treatment of asthma
GSK announced that the FDA has approved Arnuity™ Ellipta® for treatment of asthma in patients aged 12 years and older.
-
GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL
GSK & GEN announced that an Independent Data Monitoring Committee (IDMC) interim analysis of a phase III study, PROLONG (OMB 112517)
-
FDA approves Flonase allergy relief for sale over-the-counter in the United States
No. 1 prescribed allergy treatment ingredient1 to be available OTC
-
GSK announces EU regulatory submission for malaria vaccine candidate RTS,S
GSK announced today that it has submitted a regulatory application to the EMA for its malaria vaccine candidate, RTS,S.
-
Results announcement for the second quarter 2014
GSK delivers Q2 2014 turnover £5.6 billion (-4%) and core EPS 19.1p (-12%) on ex-divestment basis (both CER). Q2 dividend 19p (+6%).
-
ViiV Healthcare presents phase III data
An investigational two drug-regimen of maraviroc with DRV/r showed inferior efficacy compared to emtricitabine/tenofovir with DRV/r.
-
Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib; phase III BRAF V600-mutant metastatic melanoma study stopped early
GSK announced that the IDMC recommended COMBI-v phase III study of Mekinist™, in combination with Tafinlar™ be stopped early.
-
GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD
GSK and Theravance, Inc. today announced the start of a global phase III study, known as IMPACT.
-
Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD
GSK & THRX announced that JMHLW has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms with COPD
-
GSK receives EU marketing authorisation for Mekinist™ (trametinib) for patients with unresectable or metastatic melanoma with a BRAF V600 mutation
GSK announced, the EC has granted marketing authorisation for trametinib as treatment of patients with unresectable/metastatic melanoma
-
GSK and Genmab receive EU authorisation for Arzerra
GSK & GEN announced today that the EC has granted marketing authorisation for a new indication for the use of Arzerra™ (ofatumumab)...
-
GSK statement in response to recent media coverage related to our China business
Following media coverage, GSK has issued the below statement.
-
GSK statement on UK Government-initiated review of antibiotic resistance
We welcome today’s announcement of a review to explore the economic issues surrounding antimicrobial resistance.
-
GSK and Save the Children offer $1 million award for healthcare innovations in developing countries that reduce child deaths
GSK and Save the Children today announced the launch of their second annual $1 million Healthcare Innovation Award.
-
GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma
GSK and THRX announced the submission of a new drug application for asthma in patients aged 12 years and older, brand name Breo® Ellipta®.
-
GSK statement on recent media coverage related to our China business
Following media coverage this weekend, GSK has issued the following statement.